ESR2 and PSMC3IP

Number of citations of the paper that reports this interaction (PubMedID 11739747)
30

Data Source:
HPRD (in vitro, two hybrid)

		ESR2	PSMC3IP
Description		estrogen receptor 2	PSMC3 interacting protein
Image			No pdb structure
GO Annotations	Cellular Component	Nuclear Chromatin Nucleus Nucleoplasm Mitochondrion	Nucleoplasm
	Molecular Function	RNA Polymerase II Proximal Promoter Sequence-specific DNA Binding DNA-binding Transcription Factor Activity, RNA Polymerase II-specific DNA Binding DNA-binding Transcription Factor Activity Steroid Hormone Receptor Activity Transcription Coactivator Activity Nuclear Receptor Activity Steroid Binding Protein Binding Zinc Ion Binding Enzyme Binding Estrogen Receptor Activity Estrogen Response Element Binding Identical Protein Binding Receptor Antagonist Activity	DNA Binding Nuclear Receptor Transcription Coactivator Activity
	Biological Process	Negative Regulation Of Transcription By RNA Polymerase II Regulation Of Transcription, DNA-templated Transcription Initiation From RNA Polymerase II Promoter Signal Transduction Cell-cell Signaling Negative Regulation Of Cell Growth Intracellular Estrogen Receptor Signaling Pathway Positive Regulation Of Transcription, DNA-templated Positive Regulation Of DNA-binding Transcription Factor Activity Negative Regulation Of Signaling Receptor Activity	Reciprocal Meiotic Recombination Positive Regulation Of Nucleic Acid-templated Transcription
Pathways		PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ESR-mediated signaling Extra-nuclear estrogen signaling	Meiotic recombination
Drugs		Diethylstilbestrol Raloxifene Estrone Tamoxifen Estradiol Trilostane Estramustine Oxybenzone Genistein Prasterone Benzophenone Phthalic Acid Pyrazole Para-Mercury-Benzenesulfonic Acid Naringenin N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide 5-Alpha-Androstane-3-Beta,17beta-Diol 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol Quercetin Afimoxifene Estriol Estrone sulfate MF101 CHF 4227 Lasofoxifene Bazedoxifene 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one Erteberel (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL Eugenol Octocrylene Enzacamene Equol 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
Diseases
GWAS		anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Atrial fibrillation ( 30061737) Chronotype ( 30696823) Cognitive ability, years of educational attainment or schizophrenia (pleiotropy) ( 31374203) Depression ( 29700475) Hematocrit ( 27863252) Hemoglobin concentration ( 27863252) Metabolite levels ( 23823483) Prostate cancer ( 26443449) Red blood cell count ( 27863252)	Colorectal or endometrial cancer ( 26621817)
Interacting Genes		98 interacting genes: AGR3 AKAP13 AKT1 ARID5A BCAS2 CALM1 CALM2 CALM3 CASC3 CASZ1 CCNC CDK8 DAP3 DDX54 DKK3 DNMT3L DNTTIP2 EP300 ESR1 IL13RA2 IL24 ITIH5 JMJD1C KAT5 KLK9 LCK LRATD2 MAD2L1 MAPK1 MAPK11 MED1 MED10 MED12 MED14 MED16 MED17 MED20 MED21 MED23 MED24 MED6 MED7 MEOX2 MKNK2 MMS19 MRC2 MSH2 NCOA1 NCOA2 NCOA3 NCOA6 NCOA7 NCOR1 NCOR2 NFKBIB NOTCH2NLA NR0B1 NR0B2 NRIP1 OXT PELP1 PIAS1 PIAS2 PIAS3 PLSCR1 PNRC1 PNRC2 PPARGC1A PPP5C PRMT2 PRSS50 PSMC3IP PSMC5 RBFOX2 RBM39 REXO4 RFX6 SERPINH1 SMAD2 SMAD3 SMAD4 SMARCE1 SP1 SRA1 SRC SREBF1 STAT5A TFF1 TRAM1 TRIM24 TRIM59 TRIP4 TXNRD1 WIPI1 YWHAH YWHAQ ZBTB17 ZNHIT3	20 interacting genes: AR AURKA BCAR3 BRMS1 CASP8 CHEK2 ERBB2 ESR1 ESR2 FGFR4 FZR1 NOTCH2 NR3C1 PIK3CA PSMC3 RB1CC1 RXRA TGFB1 THRB XRCC3
Entrez ID		2100	29893
HPRD ID		03390	16362
Ensembl ID		ENSG00000140009	ENSG00000131470
Uniprot IDs		A0A348FV93 F1D8N3 Q0PTK2 Q7LCB3 Q92731	A0A158RUX1 K7ERB6 Q9P2W1
PDB IDs		1L2J 1NDE 1QKM 1U3Q 1U3R 1U3S 1U9E 1X76 1X78 1X7B 1X7J 1YY4 1YYE 1ZAF 2FSZ 2GIU 2I0G 2JJ3 2NV7 2QTU 2YJD 2YLY 2Z4B 3OLL 3OLS 3OMO 3OMP 3OMQ 4J24 4J26 4ZI1 5TOA
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?